Docstoc

2012 | Aarkstore.com || Dengue – Pipeline Review, H2 2012

Document Sample
2012 | Aarkstore.com || Dengue – Pipeline Review, H2 2012 Powered By Docstoc
					Aarkstore.com announces, The Latest market research report is available in
its vast collection:

Dengue – Pipeline Review, H2 2012




You can also request for sample page of above mention reports on
sample@aarkstore.com


Summary

Global Markets Direct’s, Dengue - Pipeline Review, H2 2012, provides an overview
of the indication’s therapeutic pipeline. This report provides information on the
therapeutic development for Dengue, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Dengue. Dengue - Pipeline Review, Half
Year is built using data and information sourced from Global Markets Direct’s
proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dengue.
- A review of the Dengue products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
Reasons to buy

- Identify and understand important and diverse types of therapeutics under
development for Dengue.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.

Table of contents:

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Dengue Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Dengue 11
Dengue Therapeutics under Development by Companies 13
Dengue Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Dengue Therapeutics – Products under Development by Companies 22
Dengue Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Dengue Therapeutics Development 24
Vical Incorporated 24
GenVec, Inc. 25
Merck & Co., Inc. 26
Biotron Limited 27
Alfacell Corporation 28
AVI BioPharma Inc. 29
Medivir AB 30
NanoViricides, Inc. 31
SIGA Technologies, Inc. 32
MacroGenics, Inc. 33
Canopus BioPharma Incorporated 34
GenPhar, Inc. 35
Ikaria Inc. 36




List of Figures

List of Tables are also include.



For more related Reports Plz follow The link:



Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1



Neutropenia – Pipeline Review, H2 2012

Amyloidosis – Pipeline Review, H2 2012

Human Papillomavirus Infections – Pipeline Review, H2 2012

Cancer Pain – Pipeline Review, H2 2012

Dengue – Pipeline Review, H2 2012
 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012

 Diabetes – Pipeline Review, H2 2012

 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012

 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,
H2 2012

 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012

 Malaria – Pipeline Review, H2 2012

 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,
H2 2012

 Dermatitis – Pipeline Review, H2 2012




Search More Reports Related to This Category :

Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1




For More details Plz do contact :

Aarkstore Enterprise

Lavanya

Phone:08149852585

Email: enquiry@aarkstore.com

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:10
posted:10/8/2012
language:
pages:5